Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ICML 2019 | Adding acalabrutinib to the arsenal: impact of ASCEND in CLL

Barbara Eichhorst • 20 Jun 2019
ICML 2019
Chronic Lymphocytic Leukemia Leukemia Acalabrutinib
ASCEND

Barbara Eichhorst, MD, University Hospital of Cologne, Cologne, Germany, discusses the ASCEND trial (NCT02970318) of acalabrutinib in relapsed/refractory chronic lymphocytic leukemia (CLL), and the potential impact of the results on clinical practice. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Barbara Eichhorst

Optimizing frontline therapy in CLL: triplet regimens and testing for MRD 1:49
Optimizing frontline therapy in CLL: triplet regimens and testing for MRD
Barbara Eichhorst • 14 Sep 2025
Practical considerations for physicians managing patients with CLL in the frontline setting 0:59
Practical considerations for physicians managing patients with CLL in the frontline setting
Barbara Eichhorst • 14 Sep 2025
A session on the management of treatment lines throughout the course of CLL 1:33
A session on the management of treatment lines throughout the course of CLL
Barbara Eichhorst • 14 Sep 2025
Epcoritamab monotherapy in first-line Richter’s transformation: 2-year follow-up of EPCORE CLL-1 1:37
Epcoritamab monotherapy in first-line Richter’s transformation: 2-year follow-up of EPCORE CLL-1
Barbara Eichhorst • 14 Sep 2025

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals